Valbiotis SA
PAR:ALVAL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Valbiotis SA
PAR:ALVAL
|
FR |
|
Northern Minerals Ltd
ASX:NTU
|
AU |
|
S
|
Shree Pacetronix Ltd
BSE:527005
|
IN |
|
Rail Vikas Nigam Ltd
NSE:RVNL
|
IN |
|
Kemira Oyj
F:KEM
|
FI |
|
Global Education Communities Corp
TSX:GEC
|
CA |
|
Hanmi Financial Corp
NASDAQ:HAFC
|
US |
|
A
|
AMAX Holding Co Ltd
TWSE:6933
|
KY |
|
Weblink International Inc
TWSE:6776
|
TW |
|
B
|
Baskent Dogalgaz Dagitim Gayrimenkul Yatirim Ortakligi AS
IST:BASGZ.E
|
TR |
|
G
|
Getin Noble Bank SA
LSE:0QA0
|
PL |
|
Meitec Corp
TSE:9744
|
JP |
|
U
|
UTS Marketing Solutions Holdings Ltd
HKEX:6113
|
MY |
|
Galane Gold Ltd
XTSX:GG
|
CA |
|
A
|
ABPro Bio Co Ltd
KOSDAQ:195990
|
KR |
|
Mr Cooper Group Inc
NASDAQ:COOP
|
US |
Valbiotis SA
Valbiotis SA develops products and candidate drugs designed to prevent metabolic diseases. The company is headquartered in Perigny, Nouvelle-Aquitaine. The company went IPO on 2017-06-07. The firm specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. The company seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The firm prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. The company provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.
Valbiotis SA develops products and candidate drugs designed to prevent metabolic diseases. The company is headquartered in Perigny, Nouvelle-Aquitaine. The company went IPO on 2017-06-07. The firm specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. The company seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The firm prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. The company provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.
